Biomarker Development for Muscular Dystrophies
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tamkin Shahraki, MD
- Phone Number: 617-726-7506
- Email: tshahraki@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Principal Investigator:
- Anthony Amato, MD
-
Contact:
- Louis Beers
- Email: lbeers@bwh.harvard.edu
-
Boston, Massachusetts, United States, 02129
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Tamkin Shahraki, MD
- Phone Number: 617-726-7506
- Email: tshahraki@mgh.harvard.edu
-
Principal Investigator:
- Thurman M. Wheeler, MD
-
Sub-Investigator:
- Paloma Gonzalez-Perez, MD, PhD
-
Boston, Massachusetts, United States, 02115
- Active, not recruiting
- Boston Children's Hospital
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest University
-
Contact:
- Constance Linville
- Phone Number: 336-716-4568
- Email: clinvill@wakehealth.edu
-
Principal Investigator:
- Araya Puwanant, MD
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh
-
Contact:
- Kerry M. Oddis, RN, CCRC
- Phone Number: 412-692-4918
- Email: kmoddis@upmc.edu
-
Principal Investigator:
- Paula R. Clemens, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects with DM1 or DM2 based on genetic testing and/or clinical criteria (some subjects who have positive genetic testing may be asymptomatic, while other subjects who show characteristic clinical features may have declined to have genetic testing done). Control non-DM subjects are unknown to have DM or any other muscular dystrophy by history and may have had no genetic testing.
- Able to provide informed consent or assent for participation in the study.
- Demographic characteristics for single biofluid collection: Males and females age 5 years and older.
- Demographic characteristics for serial biofluid and muscle function testing: Males and females age 14 years and older with DM1.
- Demographic characteristics for biofluid and muscle biopsy: Males and females, ages 18-65 years.
Demographic characteristics for single biofluid collection, ultrasound, and myography: Males and females age 14 years and older.
Exclusion Criteria:
- Medical history of any of the following. State of immunosuppression; coagulopathy; pre-existing liver or kidney disease; documented HIV positive; documented hepatitis B and/or C positive.
- Medications and other drugs. Use of anti-platelet drugs within 7 days prior to blood draw or biopsy; use of anticoagulants within 60 days prior to blood draw or biopsy; active drug or alcohol use or dependence that, in the opinion of the biopsy surgeon, would interfere with post-procedure wound care.
- Other. Inability or unwillingness of the subject to give written informed consent.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Single biofluid collection
We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
|
|
Serial biofluid and muscle function testing
We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
|
|
Biofluid and muscle tissue biopsy
We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
|
|
Ultrasound and myography testing
We will ask eligible volunteers to provide a single urine sample, a single blood draw, and undergo ultrasound and electrical impedance myography studies once.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Extracellular RNA in biofluids
Time Frame: 6 years
|
The extracellular RNA biomarkers in the muscular dystrophy groups will be evaluated and compared with the extracellular RNA content in control groups.
Statistical analysis will be used to evaluate the sensitivity and specificity of these markers as measurements of disease activity and severity based on clinical measurements of muscle power, electrocardiogram parameters, pulmonary function test parameters, muscle tissue composition using quantitative ultrasound and electrical impedance myography, and muscle tissue specimens.
|
6 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Thurman M. Wheeler, MD, Massachusetts General Hospital
Publications and helpful links
General Publications
- Antoury L, Hu N, Balaj L, Das S, Georghiou S, Darras B, Clark T, Breakefield XO, Wheeler TM. Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun. 2018 Sep 25;9(1):3906. doi: 10.1038/s41467-018-06206-0.
- Antoury L, Hu N, Darras B, Wheeler TM. Urine mRNA to identify a novel pseudoexon causing dystrophinopathy. Ann Clin Transl Neurol. 2019 May 17;6(6):1106-1112. doi: 10.1002/acn3.777. eCollection 2019 Jun.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Nervous System Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Genetic Diseases, X-Linked
- Muscular Disorders, Atrophic
- Muscular Dystrophies
- Myotonic Disorders
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Myotonic Dystrophy
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy, Facioscapulohumeral
Other Study ID Numbers
Other Study ID Numbers
- 2014P001727
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.